The relationship between of ACE I/D and the MTHFR C677T polymorphisms in the pathophysiology of type 2 diabetes mellitus in a population of Brazilian obese patients.

Objectives This study aimed to evaluate the frequencies of the angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) and methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphisms in obese patients with and without type 2 diabetes mellitus (T2DM). Subjects and methods These polymorphisms were analyzed by polymerase chain reaction in 125 patients with obesity, 47 (T2DM) and 78 (Control Group). Results No significant difference was found on comparing the T2DM and Control Groups in respect to the genotypic frequencies of the polymorphisms - (II: 13.3% vs. 12.0%; ID: 37.8% vs. 37.3; DD: 48.9% vs. 50.7%; CC: 36.2% vs. 39.0%; CT: 46.8% vs. 49.3%; TT: 17.0% vs. 11.7%), and alleles (I: 32.2% vs. 30.7%; D: 67.8% vs. 69.3%; C: 59.6% vs. 63.6%; T: 40.4% vs. 36.4%) and their synergisms in the pathophysiology of T2DM. On analyzing the T2DM Group, there were no significant differences in the presence of complications. In this population of Brazilian obese patients, no correlation was found between the ACE and MTHFR polymorphisms in the development of T2DM. Conclusion Analyzing only the group with diabetes, there was also no relationship between these polymorphisms and comorbidities.

The relationship between of ACE I/D and the MTHFR C677T polymorphisms in the pathophysiology of type 2 diabetes mellitus in a population of Brazilian obese patients

ABSTRACT Objectives This study aimed to evaluate the frequencies of the angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) and methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphisms in obese patients with and without type 2 diabetes mellitus (T2DM). Subjects and methods These polymorphisms were analyzed by polymerase chain reaction in 125 patients with obesity, 47 (T2DM) and 78 (Control Group). Results No significant difference was found on comparing the T2DM and Control Groups in respect to the genotypic frequencies of the polymorphisms - (II: 13.3% vs. 12.0%; ID: 37.8% vs. 37.3; DD: 48.9% vs. 50.7%; CC: 36.2% vs. 39.0%; CT: 46.8% vs. 49.3%; TT: 17.0% vs. 11.7%), and alleles (I: 32.2% vs. 30.7%; D: 67.8% vs. 69.3%; C: 59.6% vs. 63.6%; T: 40.4% vs. 36.4%) and their synergisms in the pathophysiology of T2DM. On analyzing the T2DM Group, there were no significant differences in the presence of complications. In this population of Brazilian obese patients, no correlation was found between the ACE and MTHFR polymorphisms in the development of T2DM. Conclusion Analyzing only the group with diabetes, there was also no relationship between these polymorphisms and comorbidities.

Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn's disease.

OBJECTIVE: The incidence of adverse events in myeloablative transplant protocols is high in refractory Crohn's disease; this study used low doses of cyclophosphamide. Fourteen patients were submitted to non-myeloablative autologous hematopoietic stem cell transplantation. RESULTS: The average number of days of anemia (hemoglobin < 10 g/dL) was 5.4 ± 4.2 and 14 ± 2.4 in the mobilization and conditioning phases, respectively. The mean number of days of neutropenia (neutrophils < 0.5 × 109/L) in the mobilization phase was 1.7 ± 1.5 while it was 7.6 ± 1.4 in the conditioning phase. When comparing the conditioning and mobilization phases, there was an increased number days of leukopenia (white blood cells < 1.0 × 109/L), lymphocytopenia (lymphocytes < 0.5 × 109/L) and thrombocytopenia (platelets < 25 × 109/L). Crohn's Disease Activity Index values before the transplant ranged from 155 to 450.5 (mean 281.2 ± 79.0) and at 30 days after the procedures they ranged from 45.4 to 177 (mean 95.8 ± 35.4). Moreover, the procedure improved in overall quality of life of patients. Non-myeloablative autologous hematopoietic stem cell transplantation with lower doses of cyclophosphamide leads to lower rates of hematological toxicity and adverse events compared to protocols described in the literature. Trial registration NCT 03000296: Date 9 December 2016.

Hipocalemia persistente: relato de caso / Persistent hypokalemia: case report

JUSTIFICATIVA E OBJETIVOS: Os distúrbios do metabolismo do potássio são comuns e tanto a reposição como o diagnóstico etiológico da hipocalemia grave e refratária em pacientes internados são um grande desafio na prática clínica. A diminuição do potássio plasmático leva a um grande prejuízo na função de nervos e músculos, podendo resultar em arritmias graves, em que o paciente na maioria das vezes apresenta-se assintomático, ou com queixas inespecíficas, como fraqueza muscular. O objetivo deste estudo foi mostrar a dificuldade no diagnóstico etiológico da hipocalemia e trazer alternativas para simplificá-lo. RELATO DO CASO: Paciente do sexo masculino, 34 anos, técnico em enfermagem, que evoluiu com hipocalemia persistentee grave. No período de dois meses evoluiu com quadro de hipertensão arterial, e, posteriormente, acne, confusão mental e diabetes com baixos valores plasmáticos de potássio apesar da reposição vigorosa, por via oral e venosa, de cloreto de potássio. Após descartar o hiperaldosteronismo, investigou-se hipercortisolismo,apesar de discretos achados fenotípicos de síndrome de Cushing. Com a confirmação do diagnóstico de doença de Cushing, o mesmo foi submetido à adrenalectomia bilateral com rápida correção dos valores pressóricos, glicêmicos e de potássio sérico. CONCLUSÃO: Diante de um caso de hipocalemia grave e refratária à reposição, torna-se indispensável o estabelecimento do diagnóstico etiológico para a correção deste grave distúrbio metabólico.

BACKGROUND AND OBJECTIVES: Metabolic disorders of potassium are common and both the replacement and the etiology of severe and refractory hypokalemia in hospitalized patients are a major challenge in clinical practice. The decrease in plasma potassium leads to a large impairment of nerves and muscles function and can result in life-threatening arrhythmias, in which the patient is most often asymptomatic or presents with nonspecific complaints, such as muscle weakness. This study aims to show the difficulty in diagnosing the etiology of hypokalemia and bring alternatives to simplify it. CASE REPORT: Male patient, 34 years-old, technical nursing has developed severe and persistent hypokalemia. In a two-month period he progressed with hypertension, and later, acne, diabetes, mental confusion and low plasma levels of potassium despite vigorous oral and intravenous potassium chloride replacement. After discarding hyperaldosteronism, hypercortisolism was investigated, although discrete phenotypic findings of Cushing's syndrome were present. Just after confirmation of Cushing's disease, the patient has undergone bilateral adrenalectomy with rapid correction of blood pressure values serum glucose and potassium. CONCLUSION: Facing a case of severe hypokalemia refractory to potassium replacement, it is essential to establish an etiological diagnosis for the correction of this serious metabolic disorder.